← Leaderboards
Theresa A Shapiro
Johns Hopkins University
$12,921,052
Attributed
$12,921,052
Total exposure
12
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $914.8K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,921,052 · 12
By mechanism
R01$8,752,700 · 3
T32$2,417,718 · 1
P01$879,909 · 2
R21$426,938 · 1
R56$410,000 · 1
M01$33,787 · 4
Top collaborators
No co-investigators on record.
Most similar at Johns Hopkins University
Same institution · by research overlap
- Paul T Englund$9,522,835
- William W Eaton$22,660,492
- Adam Peter Spira$20,411,317
- Paul Talalay$3,109,089
- Kathy J Helzlsouer$7,655,009
Others in their field
Top investigators on “Malaria”
- Lawrence Corey · Fred Hutchinson Cancer Center$227,738,417
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$227,738,417
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$82,291,297
- Stephen Lev Hoffman · Sanaria, Inc.$79,440,588
- Constance Ann Benson · University Of California, San Diego$65,790,143
- David Heimbrook · Leidos Biomedical Research, Inc.$61,561,099
Research focus
MalariaIn VitroParasitesPlasmodium FalciparumDoseDrug ResistanceDrug KineticsAtovaquonePharmaceutical PreparationsResistanceAntimalarialsPharmacodynamicsResourcesReportingChloroguanideInfectionDrug CandidateArtemisininsAffectGrantAnti-Bacterial AgentsPlasmaClinical TrialsExperimental Study
Grant awards (50)
Paired inhibition of falciparum merozoite invasion$426,938
R21 · FY2025 · AI · contact PI
Essential PK/PD relationships of antimalarial drugs$438,300
R01 · FY2024 · AI · contact PI
Essential PK/PD relationships of antimalarial drugs$438,300
R01 · FY2023 · AI · contact PI
Essential PK/PD relationships of antimalarial drugs$438,300
R01 · FY2022 · AI · contact PI
A Chemical Vaccine for Malaria$473,670
R01 · FY2021 · AI · contact PI
Essential PK/PD relationships of antimalarial drugs$438,300
R01 · FY2021 · AI · contact PI
A Chemical Vaccine for Malaria$476,454
R01 · FY2020 · AI · contact PI
Essential PK/PD relationships of antimalarial drugs$438,300
R01 · FY2020 · AI · contact PI
A Chemical Vaccine for Malaria$481,402
R01 · FY2019 · AI · contact PI
Essential PK/PD Relationships of Antimalarial and Antitrypanosomal Drugs$364,500
R01 · FY2019 · AI · contact PI
Essential PK/PD Relationships of Antimalarial and Antitrypanosomal Drugs$364,500
R01 · FY2018 · AI · contact PI
Essential PK/PD Relationships of Antimalarial and Antitrypanosomal Drugs$364,500
R01 · FY2017 · AI · contact PI
Essential PK/PD Relationships of Antimalarial and Antitrypanosomal Drugs$364,500
R01 · FY2016 · AI · contact PI
Essential PK/PD Relationships of Antimalarial and Antitrypanosomal Drugs$364,500
R01 · FY2015 · AI · contact PI
Clinical Pharmacology Training Program$257,712
T32 · FY2015 · GM · contact PI
Essential PK/PD Relationships of Antimalarial and Antitrypanosomal Drugs$283,500
R01 · FY2014 · AI · contact PI
Clinical Pharmacology Training Program$251,841
T32 · FY2014 · GM · contact PI
Essential PK/PD Relationships of Antimalarial and Antitrypanosomal Drugs$266,490
R01 · FY2013 · AI · contact PI
Clinical Pharmacology Training Program$250,597
T32 · FY2013 · GM · contact PI
Essential PK/PD Relationships of Antimalarial and Antitrypanosomal Drugs$283,500
R01 · FY2012 · AI · contact PI
Clinical Pharmacology Training Program$89,865
T32 · FY2012 · GM · contact PI
Clinical Pharmacology Training Program$225,636
T32 · FY2011 · GM · contact PI
Clinical Pharmacology Training Program$214,126
T32 · FY2010 · GM · contact PI
Topoisomerases: Target for Antitrypanosomal Therapy$410,000
R56 · FY2009 · AI · contact PI
Clinical Pharmacology Training Program$232,644
T32 · FY2009 · GM · contact PI
Clinical Pharmacology Training Program$210,084
T32 · FY2008 · GM · contact PI
EFFICACY AND SAFETY IN MAMMALIAN SYSTEMS$132,804
P01 · FY2008 · AI · contact PI
EFFICACY AND SAFETY IN MAMMALIAN SYSTEMS$131,692
P01 · FY2007 · AI · contact PI
Clinical Pharmacology Training Program$112,246
T32 · FY2007 · GM · contact PI
PHLEBOTOMY OF NORMAL VOLUNTEERS TO SUPPORT PLASMODIUM FALCIPARUM CULTURES$1,163
M01 · FY2007 · RR · contact PI
Topoisomerases: Target for Antitrypanosomal Therapy$399,144
R01 · FY2006 · AI · contact PI
Clinical Pharmacology Training Program$146,718
T32 · FY2006 · GM · contact PI
EFFICACY AND SAFETY IN MAMMALIAN SYSTEMS$134,842
P01 · FY2006 · AI · contact PI
PHLEBOTOMY OF NORMAL VOLUNTEERS TO SUPPORT PLASMODIUM FALCIPARUM CULTURES$7,672
M01 · FY2006 · RR · contact PI
Topoisomerases: Target for Antitrypanosomal Therapy$408,750
R01 · FY2005 · AI
Clinical Pharmacology Training Program$142,610
T32 · FY2005 · GM
EFFICACY AND SAFETY IN MAMMALIAN SYSTEMS$131,435
P01 · FY2005 · AI
PHLEBOTOMY OF NORMAL VOLUNTEERS TO SUPPORT PLASMODIUM FALCIPARUM CULTURES$14,454
M01 · FY2005 · RR
Topoisomerases: Target for Antitrypanosomal Therapy$408,750
R01 · FY2004 · AI
Clinical Pharmacology Training Program$142,610
T32 · FY2004 · GM
EFFICACY AND SAFETY IN MAMMALIAN SYSTEMS$128,248
P01 · FY2004 · AI
Phlebotomy of Normal Volunteers to Support Plasmodium Falciparum Cultures$10,498
M01 · FY2004 · RR
Clinical Pharmacology Training Program$141,029
T32 · FY2003 · GM
TOPOISOMERASES--TARGET FOR ANTITRYPANOSOMAL THERAPY$430,541
R01 · FY2002 · AI
PHLEBOTOMY OF NORMAL VOLUNTEERS TO SUPPORT PLASMODIUM FALCIPARUM$0
M01 · FY2002 · RR
TOPOISOMERASES--TARGET FOR ANTITRYPANOSOMAL THERAPY$419,885
R01 · FY2001 · AI
PHLEBOTOMY OF NORMAL VOLUNTEERS TO SUPPORT PLASMODIUM FALCIPARUM$0
M01 · FY2001 · RR
TOPOISOMERASES--TARGET FOR ANTITRYPANOSOMAL THERAPY$406,614
R01 · FY2000 · AI
EVALUATION IN HUMANS OF PHASE 2 ENZYME INDUCERS OF EDIBLE PLANTS$220,888
P01 · FY2000 · CA
PHLEBOTOMY OF NORMAL VOLUNTEERS TO SUPPORT PLASMODIUM FALCIPARUM$0
M01 · FY2000 · RR